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Abstract. A comparative study was performed to assess the efficiency of more approaches for 
a total number of 158 clinical cases with pseudomonads. For all these cases, the diagnostic of this 
disease was confirmed by using bacteriological examination methods. The therapy included the 
administration of several types of antibiotics, chemotherapeutical substances and vitamins, for some 
cases even anti-inflammatory substances. The proficiency results were observed after the vitamins’ 
administration associated with the therapy with antibiotics, for a relative long period of time 
(Enrofloxacin, Streptomycin with Penicillin, Colistin-sulphite etc., administrated for 15 – 21 days) and 
anti-inflammatory-therapy (Dexamethasone). 
 




In Pseudomonas genus, aeruginosa and fluorescens species are the most important 
from clinical point of view, especially for aviary pathology, in which this bacteria produces 
systemic and localized infections. Pseudomonas infections, either systemic or localized, are 
met on a large number of birds, either domestic or wild ones, and produce a series of losses to 
intensive agriculture, through their large distribution and the frequent emergence. The losses 
consist mostly of: high mortality rate, especially in chicken, the decrease of hatching 
percentage, decreases in egg production. The behavior of Pseudomonas aeruginosa and Psd. 
Fluorescens towards the action of the antibiotics remains on of the modern problems in 
pathology, in this sense being proven the natural resistance of the bacterium considering the 
majority of available antibiotics, relative often gaining of resistance towards antibiotics 
(initially sensitive to), and also the high toxicity of efficient antibiotics for the organism 
subjected to treatment.  
The antibiotics activity towards the pseudomonads is manifested in concordance with 
their capacity to penetrate through the cell wall, with their resistance to the inactivating action 
of bacterial enzymes and the affinity of the antibiotic for several structures of the cell. In turn, 
Pseudomonas aeruginosa can prevent the action of the antibiotics, using one of these 
mechanisms: the elaboration of some alternative systems which can replace or substitute the 
inhibited one; the target enzyme action decrease, this preserving its normal structure and the 
substitution of its activity through other metabolic routes; the inhibiting agent exclusion from 
the target places, through the decrease of the cell wall permeability or the production of some 
surface macromolecules; the destruction of the antibiotic through hydrolysis, the substitution 
of some chemical groups of the antibiotic. 
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The first antibiotics which proved to be efficient towards Pseudomonas spp. were 
polymyxin B, used since 1947 and colistin (polymyxin E) used since 1950. However, they 
present a high toxicity especially considering the kidneys and the nervous system. In 1963 it 
was introduced gentamicin, for the treatment of Pseudomonas aeruginosa infections, an very 
active aminoglycoside, afterwards, due to the efficiency decrease, it was replaced with 
penicillin group antibiotics (carbenicillin, piperacillin, apalcillin, phurasocillin, pirbenicillin, 
ticarcillin, azlocillin, etc.), cephalosporins (ceftazidime, cephsulodine), aminoglycosides 
(tobramycin, amikacin, dobekacillin, sislomicin), cephsulodine and ceftazidime being the 
most efficient of all. Generally, Pseudomonas aeruginosa is resistant to most of the antibiotics 
and chemotherapeuticals, including kanamycin, in comparison to other fluorescent 
pseudomonads. Taking into account these facts, the research was conducted in order to 
construct an optimal therapeutical scheme, to fight against pseudomonads, which evolve at 
cage psittacines.  
 
MATERIALS AND METHODS 
 
The study was performed on a total number of 158 clinical psittacine cases, diagnosed 
with pseudomonad, 76 of them produced by Pseudomonas aeruginosa and 82 cases produced 
by Pseudomonas fluorescens. For all the cases, the pseudomonad diagnosis was confirmed 
through bacteriological methods (Api and Rida galleries).  
As therapeutical approaches, there were different treatment schemes organized and 
applied, comprising only antibiotics, antibiotics and anti-inflammatory substances, antibiotics 
and vitamins, complex therapies with antibiotics in association with anti-inflammatory 
substances. There were used different antibiotics, either associated or alone: oxytetracycline, 
doxycycline, enrofloxacin, amoxicillin and clavulanic acid, streptomycin, streptomycin and 
penicillin. As anti-inflammatory substances, the most frequently used was dexamethasone. 
The antibiotics were administrated for a long period of time, for 15-21 days, and the 
administration of anti-inflammatories was unique and repeated at 48 hours, especially with the 
purpose of fighting against the toxic shock on clinical cases with subacute-chronical forms, 
with obvious nervous manifestations.  
The administration path was frequently the oral one, because most of the 
pharmaceutical products can provoke irritations or local necrosis, through parenteral path. 
Generally, the administration of pharmaceutical products was made either directly (through 
oral forced administration), at 8-12 hours, considering the type of product or the type of 
antibiotic.  
 
RESULTS AND DISCUSSIONS 
 
All the clinical cases were monitored through the treatment period, periodically being 
performed bacteriological analysis in order to establish the efficiency of the applied 
treatments. The comparative analysis of the obtained results allowed to observe the 
inefficiency for most of the used antibiotics, especially when these were used as an unique 
therapeutical method. Better results were obtained in the cases were the antibiotics were 
associated during the therapy, or the antibiotics were associated with anti-inflammatory 
substances, for a period of 21 days.  
The clinical cases in which the antibiotherapy was performed with cyclines or 
quinolones presented remissions of the clinical signs, but there were situations when the 
infections reappeared, when these needed a new anti-infectious therapy. In these cases, 
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generally the clinicians betook to the administration of certain types of antibiotics, frequently 
associated with dexamethasone.  
In 4 cases diagnosed with Pseudomonas fluorescens, immediately after pseudomonad 
confirmation, a streptomycin associated with penicillin and dexamethasone was established, 
the treatment being applied for 21 days. Although the clinical signs was totally remitted, the 
bacteriological examinations (at 90 days and 180 days after therapy finalization), the 
diagnosis was reconfirmed, being necessary a new administration of anti-infectious products 
(antibiotherapy), for 21 days.  
In 2 clinical cases diagnosed with Pseduomonas aeruginosa, in the first stage a therapy 
of oxytetracycline was established, for 15 days, though without any results. At 30 days after 
the first treatment, a new therapy was applied, this time with streptomycin, for 21 days, being 
observed the total remission of the clinical signs. At approximately 30-90 days from the 
second treatment, the clinical signs fell back on, and the pseudomonad diagnosis was 
reconfirmed through bacteriological examination. He antibiotherapy comprised enrofloxacin, 
associated with dexamethasone, for 21 days. Although the clinical signs were totally remitted, 
at control examinations (at 90 days and 180 days from therapy finalization), the diagnosis was 
reconfirmed, being necessary the reestablishment of a anti-infectious therapy.  
Cefsulodine is efficient almost exclusively on Pseudomonas aeruginosa. However, its 
narrow specter has the disadvantage of frequent overinfections. This is the reason for which it 
is associated with different other antibiotics. Due to the lack of adverse reactions and the 
toxicity, it is considered the best antibiotic for the last 20 years. Ceftazidime is the most active 
cephalosporin, including here also the Pseudomonas aeruginosa strains that are resistant to 
cefsulodine, not presenting crossed resistance with carbenicillin. Among aminoglycosides, 
streptomycin and neomycin are weakly active on Pseudomonas aeruginosa strains, 
manifesting a marked resistance. Kanamycin was used in Pseudomonas aeruginosa infections, 
with good results, but the sudden emergence of a large number of resistant Pseudomonas 
aeruginosa strains determined a limitation in its use.  
Gentamicin, used for pseudomonads since 1963, proved to be very efficient towards 
Pseudomonas aeruginosa strains, but it leads quickly to antibiotic resistance phenomena. 
Tobramycin, with a similar specter as gentamicin, is 2-4 times more active than this one. This 
antibiotic is active in 20-60 % on Pseudomonas aeruginosa strains resistant to gentamicin 
action, having a low incidence of toxic effects. It has been observed the emergence of several 
resistant strains for this antibiotic too (8). Aminoglycosides, with a anti-pseudomonads 
activity are: dibekacin, with an activity similar to tobramycin, sisomicin,  netilmicin and 5-
episisomicin (derived from sisomicin), habekacin, derived from dibekacin, active on 
kanamycin-resistant germs, gentamicin, tobramycin. Taking into account these results, it is 
considered that the most active antipseudomonad aminoglycosides are appreciated to be 
tobramycin, dibekacin and sisomicin.  
Considering the action of several antimicrobial agents towards the strains of 
Pseudomonas aeruginosa, it was observed in most of the situations, an almost total resistance 




1. The antibiotics with the most intense action in pseudomonads cases are 
streptomycin associated with penicillin. It is recommended the association with 
dexamethasone. The therapy can be established for a period of 21 days.  
 333 
2. The antibiotics from cycline or quinolone groups proved to be efficient in cage 
psittacine pseudomonads.  
3. The treatment plan with the best results is: associated administration of 
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